- Home
- GAM vs XERS Comparison
GAM vs XERS Comparison
Compare GAM & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAM | XERS |
|---|---|---|
| Founded | 1927 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GAM | XERS |
|---|---|---|
| Price | $60.35 | $7.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.43 |
| AVG Volume (30 Days) | 20.1K | ★ 2.5M |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 11.67 | N/A |
| Revenue | N/A | ★ $266,137,000.00 |
| Revenue This Year | N/A | $44.77 |
| Revenue Next Year | N/A | $27.72 |
| P/E Ratio | $3.95 | ★ N/A |
| Revenue Growth | N/A | ★ 42.05 |
| 52 Week Low | $37.32 | $3.21 |
| 52 Week High | $46.48 | $10.08 |
Technical Indicators
Market Signals| Indicator | GAM | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 52.31 |
| Support Level | $59.75 | $7.25 |
| Resistance Level | $61.14 | $8.42 |
| Average True Range (ATR) | 0.89 | 0.43 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 62.96 | 44.66 |
Price Performance
Historical ComparisonAbout GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).